CD274 and cancer: Since PD-L1 tumor staining by immunohistochemical is routinely used as an immunotherapy biomarker in multiple cancer types including NSCLC, further studies to investigate the relationship between BRGPs signature and PD-L1 expression are urgently warranted both in the mRNA and protein levels.